Robert J. MacKay
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Robert J. MacKay has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
J. A. Burrow
Department of Large Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville, Florida, USA
2 shared publicationsL. C. Sanchez
Department of Large Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville, Florida, USA
2 shared publications- L. Chris Sanchez
Department of Large Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville, FL
2 shared publications - Laura Patterson Rosa
Department of Veterinary Clinical Sciences, Lewyt College of Veterinary Medicine, Long Island University, Brookville, NY 11548, USA
2 shared publications M. F. Mallicote
Department of Large Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville, Florida, USA
2 shared publications- Martha F. Mallicote
Department of Large Animal Clinical Sciences, University of Florida, College of Veterinary Medicine , Gainesville, FL 32611
2 shared publications
Latest Publications
- 21 February 2022
- Published by Wiley in Veterinary Radiology & Ultrasound
- Vol. 63 (4) , 450-455
Magnetic resonance imaging of the normal equine pituitary gland
Magnetic resonance imaging is increasingly available for evaluation of horses with suspected pituitary adenomas; however, published studies describing the MRI features of normal equine pituitary glands are currently lacking. This retrospective, descriptive, anatomic study describes the MRI appearance and size of presumed normal equine pituitary glands and assesses potential correlations between pituitary size, brain size, and patient weight. These findings serve as a reference for MRI evaluation of the equine pituitary gland. Inclusion criteria consisted of adult horses (2–15 years old), over 300 kg with no evidence of Pituitary pars intermedia dysfunction (PPID) and no pituitary abnormalities identified with MRI, yielding 27 horses. Histology was available on seven pituitary glands; all were considered normal by a board‐certified anatomic pathologist. Imaging features of the glands were evaluated on T2‐weighted and pre‐ and postcontrast T1‐weighted images. Pituitary length, width, and height and brain height and width were measured by two authors on transverse and mid‐sagittal plane postcontrast T1 weighted images. The mean ± SD pituitary gland width was 21.0 ± 2.4 mm, height: 10.4 ± 1.9 mm, and length: 24.5 ± 2.7 mm. There were no significant correlations using a Pearson's correlation coefficient between pituitary and brain measurements, pituitary measurement, and body weight, or between brain measurements and body weight. A statistical difference was not identified using an unpaired t‐test (p > 0.05) in pituitary and brain measurements between necropsied and non‐necropsied horses. Relative to the cerebral white matter, all pituitary glands were isointense to slightly hyperintense on T1‐weighted images and isointense on T2‐weighted images, with the exception of a focal T1‐weighted hyperintensity that was present in the caudal aspect of the pituitary gland in 88% of horses. All pituitary glands were homogenously contrast enhancing. Pituitary dimensions did not correlate with either brain size or body weight in horses.
- 21 February 2022
- Published by Wiley in Veterinary Radiology & Ultrasound
- Vol. 63 (4) , 450-455
Magnetic resonance imaging of the normal equine pituitary gland
Magnetic resonance imaging is increasingly available for evaluation of horses with suspected pituitary adenomas; however, published studies describing the MRI features of normal equine pituitary glands are currently lacking. This retrospective, descriptive, anatomic study describes the MRI appearance and size of presumed normal equine pituitary glands and assesses potential correlations between pituitary size, brain size, and patient weight. These findings serve as a reference for MRI evaluation of the equine pituitary gland. Inclusion criteria consisted of adult horses (2–15 years old), over 300 kg with no evidence of Pituitary pars intermedia dysfunction (PPID) and no pituitary abnormalities identified with MRI, yielding 27 horses. Histology was available on seven pituitary glands; all were considered normal by a board‐certified anatomic pathologist. Imaging features of the glands were evaluated on T2‐weighted and pre‐ and postcontrast T1‐weighted images. Pituitary length, width, and height and brain height and width were measured by two authors on transverse and mid‐sagittal plane postcontrast T1 weighted images. The mean ± SD pituitary gland width was 21.0 ± 2.4 mm, height: 10.4 ± 1.9 mm, and length: 24.5 ± 2.7 mm. There were no significant correlations using a Pearson's correlation coefficient between pituitary and brain measurements, pituitary measurement, and body weight, or between brain measurements and body weight. A statistical difference was not identified using an unpaired t‐test (p > 0.05) in pituitary and brain measurements between necropsied and non‐necropsied horses. Relative to the cerebral white matter, all pituitary glands were isointense to slightly hyperintense on T1‐weighted images and isointense on T2‐weighted images, with the exception of a focal T1‐weighted hyperintensity that was present in the caudal aspect of the pituitary gland in 88% of horses. All pituitary glands were homogenously contrast enhancing. Pituitary dimensions did not correlate with either brain size or body weight in horses.
- Open Access
Ion Channel and Ubiquitin Differential Expression during Erythromycin-Induced Anhidrosis in Foals
Macrolide drugs are the treatment of choice for Rhodococcus equi infections, despite severe side-effects temporary anhidrosis as a. To better understand the molecular biology leading to macrolide induced anhidrosis, we performed skin biopsies and Quantitative Intradermal Terbutaline Sweat Tests (QITSTs) in six healthy pony-cross foals for three different timepoints during erythromycin administration—pre-treatment (baseline), during anhidrosis and post-recovery. RNA sequencing of biopsies followed by differential gene expression analysis compared both pre and post normal sweating timepoints to the erythromycin induced anhidrosis episode. After Bonferroni correction for multiple testing, 132 gene transcripts were significantly differentially expressed during the anhidrotic timepoint. Gene ontology analysis of the full differentially expressed gene set identified over-represented biological functions for ubiquitination and ion-channel function, both biologically relevant to sweat production. These same mechanisms were previously implicated in heritable equine idiopathic anhidrosis and sweat gland function and their involvement in macrolide-induced temporary anhidrosis warrants further investigation.
Open AccessIon Channel and Ubiquitin Differential Expression during Erythromycin-Induced Anhidrosis in Foals
Macrolide drugs are the treatment of choice for Rhodococcus equi infections, despite severe side-effects temporary anhidrosis as a. To better understand the molecular biology leading to macrolide induced anhidrosis, we performed skin biopsies and Quantitative Intradermal Terbutaline Sweat Tests (QITSTs) in six healthy pony-cross foals for three different timepoints during erythromycin administration—pre-treatment (baseline), during anhidrosis and post-recovery. RNA sequencing of biopsies followed by differential gene expression analysis compared both pre and post normal sweating timepoints to the erythromycin induced anhidrosis episode. After Bonferroni correction for multiple testing, 132 gene transcripts were significantly differentially expressed during the anhidrotic timepoint. Gene ontology analysis of the full differentially expressed gene set identified over-represented biological functions for ubiquitination and ion-channel function, both biologically relevant to sweat production. These same mechanisms were previously implicated in heritable equine idiopathic anhidrosis and sweat gland function and their involvement in macrolide-induced temporary anhidrosis warrants further investigation.
- Open Access
- 1 November 2021
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 141 (11) , 2639-2645.e3
Genomic Association of Chronic Idiopathic Anhidrosis to a Potassium Channel Subunit in a Large Animal Model
- 1 November 2021
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 141 (11) , 2639-2645.e3
Open AccessGenomic Association of Chronic Idiopathic Anhidrosis to a Potassium Channel Subunit in a Large Animal Model
- 28 December 2020
- Published by Wiley in Equine Veterinary Journal
- Vol. 54 (1) , 145-152
Plasma l ‐indospicine and 3‐nitropropionic acid in ponies fed creeping indigo: Comparison with results from an episode of presumptive creeping indigo toxicosis
Background: Creeping indigo ( Indigofera spicata ) toxicosis is an emerging problem among horses in Florida and bordering states. Objectives: To quantify the putative toxins l ‐indospicine (IND) and 3‐nitropropionic acid (NPA) in creeping indigo collected from multiple sites and to measure plasma toxin concentrations in ponies fed creeping indigo and horses with presumptive creeping indigo toxicosis. Study design: Experimental descriptive study with descriptive observational field investigation. Methods: Air‐dried creeping indigo was assayed for IND and NPA content. Five ponies were fed chopped creeping indigo containing 1 mg/kg/day of IND and trace amounts of NPA for 5 days, then observed for 28 days. Blood samples from these ponies and from horses involved in a presumptive creeping indigo toxicosis were assayed for IND and NPA. Results: IND in creeping indigo plants was 0.4‐3.5 mg/g dry matter whereas NPA was p = .04) and significant increase from baseline plasma protein concentration (median 16 g/L, range 8‐25 g/L; p < .001). These changes could not definitively be ascribed to creeping indigo ingestion. Plasma IND rose to 3.9 ± 0.52 mg/L on day 6. Pharmacokinetic modelling indicated an elimination half‐life of 25 days and a steady state plasma concentration of 22 mg/L. Plasma IND concentration in sick horses during an incident of creeping indigo toxicosis was approximately twice that of clinically normal pasture mates. Plasma NPA was <0.05 mg/L in all samples. Main limitations: Creeping indigo used in the feeding trial may not be representative of plants involved in creeping indigo toxicosis. There was no control group without creeping indigo in the feeding trial. Conclusions: Indospicine can be detected in blood of horses consuming creeping indigo and the toxin accumulates in tissues and clears slowly. The role of NPA in the neurological signs of this syndrome is unclear.
- 28 December 2020
- Published by Wiley in Equine Veterinary Journal
- Vol. 54 (1) , 145-152
Plasma l ‐indospicine and 3‐nitropropionic acid in ponies fed creeping indigo: Comparison with results from an episode of presumptive creeping indigo toxicosis
Background: Creeping indigo ( Indigofera spicata ) toxicosis is an emerging problem among horses in Florida and bordering states. Objectives: To quantify the putative toxins l ‐indospicine (IND) and 3‐nitropropionic acid (NPA) in creeping indigo collected from multiple sites and to measure plasma toxin concentrations in ponies fed creeping indigo and horses with presumptive creeping indigo toxicosis. Study design: Experimental descriptive study with descriptive observational field investigation. Methods: Air‐dried creeping indigo was assayed for IND and NPA content. Five ponies were fed chopped creeping indigo containing 1 mg/kg/day of IND and trace amounts of NPA for 5 days, then observed for 28 days. Blood samples from these ponies and from horses involved in a presumptive creeping indigo toxicosis were assayed for IND and NPA. Results: IND in creeping indigo plants was 0.4‐3.5 mg/g dry matter whereas NPA was p = .04) and significant increase from baseline plasma protein concentration (median 16 g/L, range 8‐25 g/L; p < .001). These changes could not definitively be ascribed to creeping indigo ingestion. Plasma IND rose to 3.9 ± 0.52 mg/L on day 6. Pharmacokinetic modelling indicated an elimination half‐life of 25 days and a steady state plasma concentration of 22 mg/L. Plasma IND concentration in sick horses during an incident of creeping indigo toxicosis was approximately twice that of clinically normal pasture mates. Plasma NPA was <0.05 mg/L in all samples. Main limitations: Creeping indigo used in the feeding trial may not be representative of plants involved in creeping indigo toxicosis. There was no control group without creeping indigo in the feeding trial. Conclusions: Indospicine can be detected in blood of horses consuming creeping indigo and the toxin accumulates in tissues and clears slowly. The role of NPA in the neurological signs of this syndrome is unclear.
- 1 August 2019
- Published by Elsevier in Veterinary Clinics of North America: Equine Practice
- Vol. 35 (2) , XI-XII
And Now for Something Completely Different: Some Controversies in Equine Medicine, Surgery, and Reproduction
- 1 August 2019
- Published by Elsevier in Veterinary Clinics of North America: Equine Practice
- Vol. 35 (2) , XI-XII
And Now for Something Completely Different: Some Controversies in Equine Medicine, Surgery, and Reproduction
- 1 August 2019
- Published by Elsevier in Veterinary Clinics of North America: Equine Practice
- Vol. 35 (2) , 311-325
Treatment Options for Melanoma of Gray Horses
- 1 August 2019
- Published by Elsevier in Veterinary Clinics of North America: Equine Practice
- Vol. 35 (2) , 311-325
Treatment Options for Melanoma of Gray Horses
- 4 September 2017
- Published by Wiley in Equine Veterinary Education
- Vol. 30 (12) , E468-E471
Pyrimethamine toxicosis in horses given a compounded medication
Summary: Eight Thoroughbred horses in race training began convulsing within 24 h of dosing with a compounded medication containing toltrazuril and pyrimethamine ( PYR ); seizures were generalised and multiple in six of the horses. One horse died within 2 h of onset and another persistently recumbent horse was subjected to euthanasia 3 days later. Neurological signs resolved within 4 days of dosing in the remaining six horses but hyperthermia, neutropenia, oral mucositis and alopecia developed in four horses beginning on Day 6. After treatment with folinic acid and folic acid for presumptive PYR ‐induced folate deficiency these signs resolved within 3 weeks. One horse developed laminitis and was ultimately subjected to euthanasia >2 months after dosing. The remaining five horses recovered and were discharged. Laboratory analysis of the suspect medication revealed that the concentrations of the two ingredients had accidentally been switched during formulation by the compounding pharmacy so that the PYR concentration was 405 g/L rather than the intended 17 g/L. This incident highlights the need for caution when using compounded preparations of potentially toxic drugs.
- 4 September 2017
- Published by Wiley in Equine Veterinary Education
- Vol. 30 (12) , E468-E471
Pyrimethamine toxicosis in horses given a compounded medication
Summary: Eight Thoroughbred horses in race training began convulsing within 24 h of dosing with a compounded medication containing toltrazuril and pyrimethamine ( PYR ); seizures were generalised and multiple in six of the horses. One horse died within 2 h of onset and another persistently recumbent horse was subjected to euthanasia 3 days later. Neurological signs resolved within 4 days of dosing in the remaining six horses but hyperthermia, neutropenia, oral mucositis and alopecia developed in four horses beginning on Day 6. After treatment with folinic acid and folic acid for presumptive PYR ‐induced folate deficiency these signs resolved within 3 weeks. One horse developed laminitis and was ultimately subjected to euthanasia >2 months after dosing. The remaining five horses recovered and were discharged. Laboratory analysis of the suspect medication revealed that the concentrations of the two ingredients had accidentally been switched during formulation by the compounding pharmacy so that the PYR concentration was 405 g/L rather than the intended 17 g/L. This incident highlights the need for caution when using compounded preparations of potentially toxic drugs.
- 29 March 2017
- Published by Wiley in Equine Veterinary Journal
- Vol. 49 (5) , 624-628
Effects of clarithromycin, azithromycin and rifampicin on terbutaline‐induced sweating in foals
Summary: Background: Erythromycin ( ERY ) induces anhidrosis in foals. Azithromycin ( AZI ) and clarithromycin ( CLA ), often combined with rifampicin ( RIF ), are commonly used to treat Rhodococcus equi infections, but effects on sweating have not been investigated. Objective: To determine the effects of AZI , CLA and RIF on sweat responses in normal foals. Study design: Each experiment was a blinded, duplicated, six foal × three period counterbalanced within subjects design (12 foals/experiment). Methods: Antimicrobials were given orally for 5 days. In Experiment 1, ERY , AZI and CLA were given. In Experiment 2, ERY , RIF and ERY / RIF combination were used. Quantitative intradermal terbutaline sweat tests were performed daily for 3 days before and 1, 2, 5, 9, 24, and 39 days after treatment. Data were analysed by repeated measures analysis of variance procedures. Significance was P≤0.05. Results: In Experiment 1, all macrolides suppressed sweating although CLA and AZI were less potent than ERY . In Experiment 2, significant sweat suppression occurred in foals given ERY with or without RIF , but there was no effect of RIF alone. Rifampicin reduced sweat suppression by ERY on Day 1 of treatment but not thereafter. Main limitations: Because ERY blood concentrations were not measured, effects of RIF on ERY ‐induced anhidrosis could not definitively be ascribed to altered ERY bioavailability. Conclusions: All macrolides commonly used to treat R. equi pneumonia, i.e. ERY , AZI and CLA , induce anhidrosis in foals. The potent anti‐sudorific effect of ERY is delayed, but not substantially affected by concurrent RIF administration.
- 29 March 2017
- Published by Wiley in Equine Veterinary Journal
- Vol. 49 (5) , 624-628
Effects of clarithromycin, azithromycin and rifampicin on terbutaline‐induced sweating in foals
Summary: Background: Erythromycin ( ERY ) induces anhidrosis in foals. Azithromycin ( AZI ) and clarithromycin ( CLA ), often combined with rifampicin ( RIF ), are commonly used to treat Rhodococcus equi infections, but effects on sweating have not been investigated. Objective: To determine the effects of AZI , CLA and RIF on sweat responses in normal foals. Study design: Each experiment was a blinded, duplicated, six foal × three period counterbalanced within subjects design (12 foals/experiment). Methods: Antimicrobials were given orally for 5 days. In Experiment 1, ERY , AZI and CLA were given. In Experiment 2, ERY , RIF and ERY / RIF combination were used. Quantitative intradermal terbutaline sweat tests were performed daily for 3 days before and 1, 2, 5, 9, 24, and 39 days after treatment. Data were analysed by repeated measures analysis of variance procedures. Significance was P≤0.05. Results: In Experiment 1, all macrolides suppressed sweating although CLA and AZI were less potent than ERY . In Experiment 2, significant sweat suppression occurred in foals given ERY with or without RIF , but there was no effect of RIF alone. Rifampicin reduced sweat suppression by ERY on Day 1 of treatment but not thereafter. Main limitations: Because ERY blood concentrations were not measured, effects of RIF on ERY ‐induced anhidrosis could not definitively be ascribed to altered ERY bioavailability. Conclusions: All macrolides commonly used to treat R. equi pneumonia, i.e. ERY , AZI and CLA , induce anhidrosis in foals. The potent anti‐sudorific effect of ERY is delayed, but not substantially affected by concurrent RIF administration.
- 7 September 2015
- Published by Wiley in Equine Veterinary Journal
- Vol. 48 (5) , 590-594
Macrolide‐induced hyperthermia in foals: Role of impaired sweat responses
Summary: Reasons for performing study: The mechanism of hyperthermia, a potentially fatal adverse effect of erythromycin treatment of foals, is unknown. Objectives: To determine the cause of erythromycin‐associated hyperthermia. It was hypothesised that the normal sweat response of foals is impaired by treatment with erythromycin. Study design: Blinded, crossover study in 10 healthy pony foals. Methods: Foals kept in stalls were given either erythromycin (25 mg/kg bwt orally, 3 times daily) or control for 10 days then turned out for a further 10 days. Quantitative intradermal terbutaline sweat tests were performed on Days 1 (baseline), 3, 10 and 20. The effects on terbutaline‐induced sweating of erythromycin, terbutaline concentration and treatment day were analysed by repeated‐measures ANOVA with Bonferroni‐corrected pairwise post hoc comparisons. Peak temperatures were compared by Wilcoxon's signed rank test and proportions by McNemar's related samples test. Significance was set at P<0.05. Results: There were significant 2‐factor interactions for treatment × terbutaline after baseline, treatment × day at every terbutaline concentration, and day × terbutaline for erythromycin (P<0.001) but not control (P = 0.9) treatment. Sweating was significantly reduced from baseline in erythromycin‐treated foals at all subsequent days. Erythromycin‐treated foals produced less sweat at all time‐points than did control‐treated foals (P<0.05). Peak rectal temperatures of erythromycin‐treated foals were significantly higher (P = 0.02) than those of controls. During the first 3 days outside more erythromycin‐treated than control‐treated foals required treatment for hyperthermia (6 vs. 0; P = 0.03). Conclusions: We believe drug‐induced anhidrosis is the likely cause of hyperthermia in some foals treated with erythromycin.
- 7 September 2015
- Published by Wiley in Equine Veterinary Journal
- Vol. 48 (5) , 590-594
Macrolide‐induced hyperthermia in foals: Role of impaired sweat responses
Summary: Reasons for performing study: The mechanism of hyperthermia, a potentially fatal adverse effect of erythromycin treatment of foals, is unknown. Objectives: To determine the cause of erythromycin‐associated hyperthermia. It was hypothesised that the normal sweat response of foals is impaired by treatment with erythromycin. Study design: Blinded, crossover study in 10 healthy pony foals. Methods: Foals kept in stalls were given either erythromycin (25 mg/kg bwt orally, 3 times daily) or control for 10 days then turned out for a further 10 days. Quantitative intradermal terbutaline sweat tests were performed on Days 1 (baseline), 3, 10 and 20. The effects on terbutaline‐induced sweating of erythromycin, terbutaline concentration and treatment day were analysed by repeated‐measures ANOVA with Bonferroni‐corrected pairwise post hoc comparisons. Peak temperatures were compared by Wilcoxon's signed rank test and proportions by McNemar's related samples test. Significance was set at P<0.05. Results: There were significant 2‐factor interactions for treatment × terbutaline after baseline, treatment × day at every terbutaline concentration, and day × terbutaline for erythromycin (P<0.001) but not control (P = 0.9) treatment. Sweating was significantly reduced from baseline in erythromycin‐treated foals at all subsequent days. Erythromycin‐treated foals produced less sweat at all time‐points than did control‐treated foals (P<0.05). Peak rectal temperatures of erythromycin‐treated foals were significantly higher (P = 0.02) than those of controls. During the first 3 days outside more erythromycin‐treated than control‐treated foals required treatment for hyperthermia (6 vs. 0; P = 0.03). Conclusions: We believe drug‐induced anhidrosis is the likely cause of hyperthermia in some foals treated with erythromycin.
- Open Access
- 7 July 2014
- Published by Springer Nature in BMC Veterinary Research
- Vol. 10 (S1) , S6
Systemic and anti-nociceptive effects of prolonged lidocaine, ketamine, and butorphanol infusions alone and in combination in healthy horses
Prolonged drug infusions are used to treat horses with severe signs of pain, but can be associated with altered gastrointestinal transit. The purpose of this study was to determine the effects of prolonged constant rate infusions (CRI) of lidocaine (L), butorphanol (B), and ketamine (K) alone and in combination on gastrointestinal transit, behavior, and thermal nociceptive threshold in healthy horses.
- 7 July 2014
- Published by Springer Nature in BMC Veterinary Research
- Vol. 10 (S1) , S6
Open AccessSystemic and anti-nociceptive effects of prolonged lidocaine, ketamine, and butorphanol infusions alone and in combination in healthy horses
Prolonged drug infusions are used to treat horses with severe signs of pain, but can be associated with altered gastrointestinal transit. The purpose of this study was to determine the effects of prolonged constant rate infusions (CRI) of lidocaine (L), butorphanol (B), and ketamine (K) alone and in combination on gastrointestinal transit, behavior, and thermal nociceptive threshold in healthy horses.